News

U.Va. biolab seeks to catalyze region’s growth

Thomas Barker says his seed-stage startup wants to find “modern, modular, functional lab space” to allow the company he co-founded, Vasarya Therapeutics, to be “very efficient and optimal on our research enterprise.”

But good lab space is hard to come by in Charlottesville, and what exists is spread around, “so you don’t necessarily get the impact of having other startup and tech companies in your space being in close proximity,” adds Barker, who is also Vasarya’s chief scientific officer.

CvilleBioHub hopes to address those problems by creating CvilleBioLab, an accelerator where early-stage companies can spend a year or two performing research while also being mentored by business leaders and advisers who can help “de-risk” the startup process, including navigating issues like intellectual property protection, says Nikki Hastings, executive director and co-founder of the nonprofit. Founded in 2016, CvilleBioHub advocates for and works to build the area’s biotech community.

In March, the organization received a $100,000 GO Virginia grant to support planning for CvilleBioLab. While there’s no timeline for site selection, CvilleBioHub’s real estate partner, Rockville, Maryland-based Scheer Partners, is searching for an existing building to convert. “Ideally, we’d like 15,000 to 20,000 square feet, although we could get started with 5,000,” Hastings says.

Depending on the size, Hastings, the biotech track director at the University of Virginia’s McIntire School of Commerce, estimates spending around $3 million for infrastructure and equipment, with operating costs for staffing, maintenance, and overhead running between $500,000 and $1 million annually. Funding is still being determined, Hastings says.

The facility will include a wet lab and equipment including refrigerators, ultra-low-temperature freezers for DNA samples and other biological material, incubators, cell culture and DNA analysis tools, and basic lab equipment like microscopes.

The lab’s buildout is expected to take about a year. Companies will apply for a spot, with six to eight startups sharing the facility, though Hastings says CvilleBioHub will use part of the planning grant to “more definitively” determine programming during the summer. A lab director and entrepreneur advisory team will support occupants.

Charlottesville-area researchers who want to spin their work into a startup would benefit from having a formal incubator, says Renna Nouwairi, a Ph.D. candidate in bioanalytical chemistry at U.Va. “It would be a shame for our city and local economy to miss out on opportunities because a startup-friendly infrastructure is not in place.”

 

Learn more here.

Recent News

05/12/2026

Phlow Corp. Appoints Tim Mayleben Chief Executive Officer as Co-Founder Dr. Eric Edwards Transitions to Chairman Emeritus and Strategic Advisor

Phlow Corp., a leading American advanced pharmaceutical contract development and manufacturing organization (CDMO), today announced that Tim Mayleben has been appointed Chief Executive Officer, effective immediately. Eric Edwards, M.D., Ph.D., Phlow’s co-founder and former CEO, has transitioned to the role of Chairman Emeritus and Strategic Advisor to the CEO and Board of Directors. The leadership

05/09/2026

NIRSense Supports the US Army in the Indo-Pacific with Tissue Oxygenation Assessment for Battlefield Casualty Care at Balikatan-26

NIRSense, Inc. today announced its participation in Balikatan-26, supporting the US Army Pacific (USARPAC)’s 18th Theater Medical Command (18th TMC) as they evaluate advanced approaches to battlefield casualty assessment using portable tissue oxygen saturation (StO₂) monitoring. Balikatan, meaning “shoulder-to-shoulder,” is the longstanding U.S.-Philippine bilateral exercise designed to strengthen interoperability and regional readiness through combined operations

05/08/2026

RIVANNA Receives FDA 510(k) Clearance for Accuro XV Musculoskeletal Ultrasound Imaging System

RIVANNA®, developer of AI-enabled clinical decision-support solutions, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Accuro® XV Diagnostic Ultrasound System. The clearance marks a pivotal regulatory milestone for RIVANNA, authorizing commercial use of the Accuro XV for musculoskeletal imaging by qualified and trained healthcare professionals in hospital